Skip to main content

Table 1 Adjustments to the DDDPZA and PZA treatment length based on notified patients’ characteristics

From: Completeness of tuberculosis case notifications in Germany in 2013–2017: first results of an inventory study

Adjustment to Notified variable Value of the notified variable Adjustment
DDDPZA* Age group 0–4 500 mg
5–10 750 mg
11–14 1250 mg
> 14 1750 mg
Treatment length Resistance against Isoniazid + Ethambutol 10.5 months (average of the recommended 9 to 12 months)
Isoniazid + Rifampicin** 18 months
PZA 0 months
Hospitalization Hospital admission and discharge dates Recommended PZA treatment time (60 days) minus number of days of hospitalization falling within PZA treatment time
Hospitalization status = “yes” Recommended PZA treatment time (60 days) minus average number of days of hospitalization*** falling within PZA treatment time
Death during treatment Date of death Recommended PZA treatment time (60 days) minus number of days between date of death and expected treatment end time
  1. *The adjustments to DDDPZA were based on patient’s age since weight is not a notifiable variable. The dosage assumed for age groups was based on the recommendations of the medication producer Riemser Arzneimittel AG, Germany, which supplied the majority of PZA in Germany from 2013-2017 (according to the PZA pharmacy data)
  2. **Multidrug-resistant TB (MDR-TB)
  3. ***Calculated based on hospitalized TB patients from the corresponding year